U.S. Markets closed

Biotech Companies to Watch

HENDERSON, NV / ACCESSWIRE / January 10, 2019 / Biotech has started 2019 off with a bang. Below are a few that you should be paying attention to.

One that looks poised for a big year, Delcath Systems, Inc. (DCTH), has impressive liver cancer treatments in late-stage development, is already in Phase 3 clinical trials, increased their revenue this past year, and just signed a licensing deal with a projected value of up to $45 million. The stock is still a relative unknown, but the street may be catching on. Do your due diligence on DCTH today.

Today we are highlighting:Delcath Systems, Inc. (DCTH), Amarin Corporation plc (AMRN), La Jolla Pharmaceutical Company (LJPC), Cronos Group, Inc. (CRON), and Geron Corporation (GERN).

An interventional oncology company focused on treating liver cancers with significant upside potential, Delcath Systems, Inc. (DCTH) (Market Cap: $2.729M, Share Price: $0.28) ended 2018 with significant news.

The company made major news when it announced a new licensing agreement for CHEMOSAT® commercialization in Europe with medac Gesellschaft für klinische Spezialpräparate mbH (medac). The agreement has a projected value of up to $45 million over the first seven-year term and includes an optional five-year extension. medac is a privately held, multi-national pharmaceutical company based in Hamburg area, Germany. Founded in 1970, medac specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases. The company has offices globally, worldwide partner agreements in over 90 countries, and approximately 1,200 employees.

The medac licensing agreement comes in addition to an announcement about the independent Data Safety Monitoring Board (DSMB) of the Registration trial for Patients with Hepatic Dominant Ocular Melanoma (The FOCUS Trial) completed another pre-specified review (the fourth) of safety data for treated patients in the trial. This review was conducted on data collected from both the prior randomized protocol and the amended single-arm protocol for the FOCUS Trial. The DSMB again recommended continuation of the study without modification.

Also, in 2018 Delcath amended their Phase 3 clinical trial, raised $7 million via a right offering, increased revenue 20% Y/Y, and had data published in European Radiology among several other milestones.


Amarin Corporation plc (AMRN) (Market Cap: $4.853B, Share Price: $15.03) recently provided a business update, including a preliminary estimate of 2018 revenue results and 2019 revenue and spending guidance. Total revenue for 2018 are estimated to have reached between $224 and $228 million, including estimated net total revenue of $72 to $76 million in Q4 2018.


La Jolla Pharmaceutical Company (LJPC) (Market Cap: $159.763M, Share Price: $6.09) plummeted after the company said it expects sales of low blood pressure drug Giapreza to hit $24 million-$28 million in 2019, roughly half of what analysts had projected. However, the stock has started to rebound a bit.


After receiving $14 billion from Altria for a 45% stake in the company, Cronos Group, Inc. (CRON) (Market Cap: $2.281B, Share Price: $12.98) continues to climb.


Geron Corporation (GERN) (Market Cap: $218.027M, Share Price: $1.17) announced that results from IMbark, a Phase 2 clinical trial of imetelstat treatment in Intermediate-2 or High-risk myelofibrosis (MF) patients who are relapsed or refractory to a Janus Kinase (JAK) inhibitor, were presented at the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, California. The oral presentation was made on December 3, 2018 by John Mascarenhas, M.D., Associate Professor of Medicine in the Myeloproliferative Disorders Program of the Tisch Cancer Institute, Division of Hematology/Oncology at the Icahn School of Medicine at Mount Sinai, and an IMbark clinical investigator.

Legal Disclaimer:

This article was written by Regal Consulting, LLC ("Regal Consulting"). Regal Consulting has agreed to a twelve-month term consulting agreement with DCTH dated 8/31/18. The agreement calls for $40,000 in cash, and 15,000 restricted 144 shares of DCTH per month. Issuer agreed to increase monthly cash payment in September to $120,000. All payments were made directly by Delcath Systems, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspecultors.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. DCTH was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.

http://www.regalconsultingllc.com/full legal disclaimer/

Microspeculators.com Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators

Contact Person: Media Manager

Email: info@microcapspeculators.com

Phone: 1-702-720-6310

Country: United States

Website: http://microcapspeculators.com/

SOURCE: Microcap Speculators